Saturday, April 13, 2024

New Study Explores Pepto-Bismol’s Ability to Kill COVID

'If we can find drugs that are currently FDA approved, cheap and readily available throughout the world... '

(Molly Bruns, Headline USA) The University of Louisville is performing a study to confirm whether or not bismuth subscalicylate, more commonly known as Pepto-Bismol, may help people with COVID-19.

According to the clinical trial, Pepto-Bismol, a popular over-the counter-medication, has one of the highest rates of antimicrobial activity against pathogenic bacteria. It also increases hydration and provides relief from symptoms.

Much of the research on the medication is not published. This study will look at 35 participants with mild COVID, ten of which will take Pepto-Bismol and 25 will receive a placebo. Participants will measure the severity of their symptoms and track their daily number of bowel movements.

The study is a collaboration between the university and Proctor and Gamble, who owns Pepto-Bismol.

The pink medication is not the only drug that is the subject of study.

The University of Virginia is in the process of testing the effects of ivermectin on the COVID virus after Democrats stirred up a great deal of controversy concerning the drug in the midst of initial lockdown panic.

“If we can find drugs that are currently FDA approved, cheap and readily available throughout the world I think that really gets us much closer to being able to turn COVID-19 into a mild illness where people can kind of get therapy,” principal investigator Dr. Patrick Jackson said.

Jackson stated that both Ivermectin and Fluvoxamine show “signs of helpfulness” when dealing with the virus, explaining that the drug even “stop[s] many viruses from replicating” when given in high doses.

Leftist reporters responded to the announcement of this study in February by pushing an alternative JAMA Network study alleging that “a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.”

Copyright 2024. No part of this site may be reproduced in whole or in part in any manner other than RSS without the permission of the copyright owner. Distribution via RSS is subject to our RSS Terms of Service and is strictly enforced. To inquire about licensing our content, use the contact form at https://headlineusa.com/advertising.
- Advertisement -